Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully

Lin, Baisheng; Du, Likun; Li, Hongmei; Zhu, Xiao; Cui, Liao; Li, Xiaosong

doi:10.1016/j.biopha.2020.110873

Cited by 93 publications

(73 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the incidence of these two kinds of hematological malignancies is increasing year by year, which undoubtedly poses a serious threat to human health and life safety. The occurrence and development of hematological malignancies are very rapid and complex, which is a complex process of the interaction between internal genetic factors (38)(39)(40)(41)(42)(43)(44), molecular signal transduction (45,46), metabolic factors (47)(48)(49), immune factors (50)(51)(52)(53)(54)(55), and tumor microenvironment (41,(56)(57)(58)(59). Although current chemotherapy can prolong the survival time of tumor patients (60,61), the prognosis and economic burden are still difficult problems in clinical work.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

N6-methyladenosine (m6A) is one of the most active modification factors of mRNA, which is closely related to cell proliferation, differentiation, and tumor development. Here, we explored the relationship between the pathogenesis of hematological malignancies and the clinicopathologic parameters. The datasets of hematological malignancies and controls were obtained from the TCGA [AML (n = 200), DLBCL (n = 48)] and GTEx [whole blood (n = 337), blood vascular artery (n = 606)]. We analyzed the m6A factor expression differences in normal tissue and tumor tissue and their correlations, clustered the express obvious clinical tumor subtypes, determined the tumor risk score, established Cox regression model, performed univariate and multivariate analysis on all datasets. We found that the AML patients with high expression of IGF2BP3, ALKBH5, and IGF2BP2 had poor survival, while the DLBCL patients with high expression of METTL14 had poor survival. In addition, “Total” datasets analysis revealed that IGF2BP1, ALKBH5, IGF2BP2, RBM15, METTL3, and ZNF217 were potential oncogenes for hematologic system tumors. Collectively, the expressions of some m6A regulators are closely related to the occurrence and development of hematologic system tumors, and the intervention of specific regulatory factors may lead to a breakthrough in the treatment in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Human MHC or Human Leukocyte Antigen 1 (HLA-I) molecules are encoded by a series of polymorphic genes with multiple alleles or haplotypes. The most common method for these allele alterations is loss of heterozygosity in the coding region of HLA and 2-microglobulin (an essential element of the HLA-I complex), resulting in loss of HLA-I haplotypes, and loss of chromosome 15 (7,17). Tumor cells also have a tendency to evade NK cell detection by regulating the expression of MHC class I-like NKG2D ligands.…”

Section: Major Histocompatibility Complexmentioning

confidence: 99%

“…Tregs can enhance immune function and help maintain homeostasis. In cancer, however, Tregs infiltrate the tumor microenvironment (7,48,49). This is associated with poor prognosis and poor response to immunotherapy.…”

Section: Regulatory T Cellsmentioning

confidence: 99%

“…The aim of tumor immunology therapy is to stimulate or mobilize the body's immune system and enhance tumor microenvironment anti-tumor immunity, so as to control and kill tumor cells (3). There are many methods of tumor immunological therapy (4) (5), including tumor vaccine (6), immune-guided therapy, cell adoptive immunotherapy (7), cytokine therapy, gene therapy (8) and comprehensive therapy. Immunotherapy of tumor, whether a single drug or combination therapy, has shown clinical efficacy in many kinds of cancer, so it has attracted more and more attention (3,9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Zhu

2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy is a kind of therapy that can control and eliminate tumors by restarting and maintaining the tumor-immune cycle and restoring the body’s normal anti-tumor immune response. Although immunotherapy has great potential, it is currently only applicable to patients with certain types of tumors, such as melanoma, lung cancer, and cancer with high mutation load and microsatellite instability, and even in these types of tumors, immunotherapy is not effective for all patients. In order to enhance the effectiveness of tumor immunotherapy, this article reviews the research progress of tumor microenvironment immunotherapy, and studies the mechanism of stimulating and mobilizing immune system to enhance anti-tumor immunity. In this review, we focused on immunotherapy against tumor microenvironment (TME) and discussed the important research progress. TME is the environment for the survival and development of tumor cells, which is composed of cell components and non-cell components; immunotherapy for TME by stimulating or mobilizing the immune system of the body, enhancing the anti-tumor immunity. The checkpoint inhibitors can effectively block the inhibitory immunoregulation, indirectly strengthen the anti-tumor immune response and improve the effect of immunotherapy. We also found the checkpoint inhibitors have brought great changes to the treatment model of advanced tumors, but the clinical treatment results show great individual differences. Based on the close attention to the future development trend of immunotherapy, this study summarized the latest progress of immunotherapy and pointed out a new direction. To study the mechanism of stimulating and mobilizing the immune system to enhance anti-tumor immunity can provide new opportunities for cancer treatment, expand the clinical application scope and effective population of cancer immunotherapy, and improve the survival rate of cancer patients.

show abstract

“…MSCs can differentiate into a variety of tissue cells derived from mesoderm and neuroectoderm, such as osteoblasts, chondrocytes, adipocytes, tenocytes, smooth muscle cells, bone marrow stromal cells, fibroblasts and a variety of vascular endothelial cells, and even neurons and glial cells of the nervous system [5][6][7]. Moreover, proteins secreted by MSCs have anti-microbial, anti-fibrotic, and regenerative effects, and have effects on cell proliferation, differentiation, immune regulation, angiogenesis, wound healing, and tissue regeneration [8][9][10]. Therefore, MSCs have become the "practical stem cells" for the treatment of multiple systemic diseases [11].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells: ideal seeds for treating diseases

Gao

Fan

et al. 2021

Human Cell

Self Cite

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), a kind of multipotent stem cells with self-renewal ability and multi-differentiation ability, have become the "practical stem cells" for the treatment of diseases. MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn's disease. MSCs also can be used in cancer and aging. At present, many clinical experiments are using MSCs. MSCs can reduce the occurrence of inflammation and apoptosis of tissue cells, and promote the proliferation of endogenous tissue and organ cells, so as to achieve the effect of repairing tissue and organs. MSCs presumably also play an important role in Corona Virus Disease 2019 (COVID-19) infection. Keywords Mesenchymal stem cells • Autoimmune diseases • Aging • Inflammation • Cancer • COVID-19 Abbreviations AA Alginate ARDS Acute respiratory distress syndrome BM-MSCs Bone marrow mesenchymal stem cells BMP-2 Bone morphogenetic protein 2 CBX4 Chromobox protein homologue 4 CRISPR Clustered Regularly Interspaced Short Palindromic Repeats Cas9 CRISPR-associated protein-9 nuclease Col Collagen COPD Chronic obstructive pulmonary disease COVID-19 Corona Virus Disease 2019 CRC Colorectal cancer CXCR7 C-X-C chemokine receptor type 7 CXCL12 C-X-C motif chemokine ligand 12

show abstract

Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully

Cited by 93 publications

References 91 publications

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Mesenchymal stem cells: ideal seeds for treating diseases

Contact Info

Product

Resources

About